{"topic_id":"ade_severity_year_trend","category":"ade","context":"---\ntopic_id: ade_severity_year_trend\ncategory: ade\ntitle: \"FDA ADE severity x annual-volume cross-cut (top 22 active ingredients)\"\nlang: en\nsource_file: pdf-raw/ade/ade_timeseries_20260816.json; pdf-raw/ade/ade_species_slice_expand_2026-08-16.json\nsource_type: open_dataset\nderived_from_dataset: ade_annual_trends_top_drugs\ndate_parsed: 2026-08-16\nlicense: \"open dataset (FDA openFDA, public domain)\"\nverification: {method: substring_match, mode: derived_from_dataset, claims: 122, passed: 122, date: 2026-08-16}\ncitation:\n  authority: \"US FDA Center for Veterinary Medicine (openFDA animal & veterinary event database)\"\n  title: \"FDA ADE severity x annual-volume cross-cut\"\n  url: \"https://api.fda.gov/animalandveterinary/event.json\"\n---\n\n# FDA ADE severity x annual-volume cross-cut (top 22 active ingredients)\n\nCross-cut of two already-landed openFDA snapshots (pulled 2026-08-16): the per-drug **annual report-count trend** (`ade_timeseries_20260816.json`) and the per-species **overall serious-adverse-event share** (`ade_species_slice_expand_2026-08-16.json`). Report-level counts; one report may list multiple reactions / animals; not additive; reported != causal.\n\n> **Honest scope note.** `serious_share` is the **all-years aggregate** for each species (openFDA does not expose year-resolved seriousness in the landed data). A true *seriousness x year* Cartesian product would require a fresh openFDA date x seriousness histogram query (network egress) and is **deferred**. Every quoted number below is a whitespace-collapsed substring of one of the two landed JSONs (C1: `substring_match`, `derived_from_dataset`).\n\n## Cross-cut table (sorted by total reports)\n\n| 药物 Active ingredient | 总报告数 Total | 峰值年 Peak yr | 峰值数 Peak n | 最新整年 2025 | Dog 严重占比 | Cat 严重占比 |\n|---|---|---|---|---|---|---|\n| pyrantel | 251640 | 2025 | 22501 | 22501 | 38.5% | 36.6% |\n| milbemycin | 236728 | 2013 | 26872 | 4938 | 13.7% | 12.6% |\n| spinosad | 212330 | 2013 | 35885 | 859 | 10.4% | 6.8% |\n| ivermectin | 194443 | 2017 | 12386 | 5519 | 34.5% | 19.3% |\n| milbemycin oxime | 193924 | 2013 | 26819 | 3773 | 13.6% | 17.0% |\n| moxidectin | 96699 | 2025 | 11740 | 11740 | 47.1% | 48.8% |\n| fluralaner | 88485 | 2018 | 9992 | 8188 | — | — |\n| sarolaner | 79692 | 2024 | 13421 | 13232 | 50.3% | 34.1% |\n| praziquantel | 79252 | 2019 | 7505 | 6563 | 16.4% | 33.7% |\n| selamectin | 71505 | 2000 | 5736 | 2207 | 6.9% | 14.4% |\n| afoxolaner | 69037 | 2017 | 7812 | 7336 | 31.7% | 31.7% |\n| carprofen | 52017 | 2000 | 4473 | 2129 | 18.4% | 3.6% |\n| oclacitinib | 29980 | 2017 | 4047 | 3060 | — | — |\n| imidacloprid | 29079 | 2017 | 2192 | 914 | 46.7% | 49.8% |\n| nitenpyram | 21322 | 2017 | 2178 | 1008 | 9.9% | 10.8% |\n| bedinvetmab | 18921 | 2024 | 10012 | 6663 | 61.8% | 0.0% |\n| meloxicam | 17181 | 2012 | 1778 | 668 | 29.5% | 22.6% |\n| lotilaner | 13432 | 2025 | 3158 | 3158 | 14.0% | 20.0% |\n| gabapentin | 10444 | 2024 | 2907 | 2607 | 56.4% | 52.5% |\n| bexagliflozin | 3835 | 2024 | 1459 | 1232 | — | — |\n| dirlotapide | 2992 | 2009 | 986 | — | — | — |\n| sirolimus | 40 | 2025 | 26 | 26 | — | — |\n\n## Reading the table\n\n- `总报告数` = sum of all annual buckets for the active ingredient (analyzed `drug.active_ingredients.name`, so it captures all formulations / brand variants).\n- `峰值年 / 峰值数` = the single calendar year with the highest report count.\n- `最新整年 2025` = report count in 2025 (the latest *complete* year; 2026 is a partial year through the 2026-08-16 snapshot and is excluded from this column).\n- `Dog 严重占比 / Cat 严重占比` = share of reports flagged serious, all-years aggregate. `—` means the drug is not in the landed species-slice snapshot (5 of 22: fluralaner, dirlotapide, oclacitinib, bexagliflozin, sirolimus).\n\n## Source & cross-references\n\n- Annual volume trend (year-resolved): `ade_annual_trends_top_drugs`\n- Per-species serious-share detail + top VEDDRA reactions: the `ade_<slug>_by_species` topics\n- Raw snapshots: `pdf-raw/ade/ade_timeseries_20260816.json`, `pdf-raw/ade/ade_species_slice_expand_2026-08-16.json`\n\n","sources":["US FDA Center for Veterinary Medicine (openFDA animal & veterinary event database) — FDA ADE severity x annual-volume cross-cut (retrieved 2026-08-16)"],"source":{"authority":"US FDA Center for Veterinary Medicine (openFDA animal & veterinary event database)","title":"FDA ADE severity x annual-volume cross-cut","url":"https://api.fda.gov/animalandveterinary/event.json","retrieved":"2026-08-16","ref":"","doc_type":"official PDF","source_document":"","verification_file":"pdf-raw/ade/ade_timeseries_20260816.json; pdf-raw/ade/ade_species_slice_expand_2026-08-16.json"},"source_document":"","source_file":"pdf-raw/ade/ade_timeseries_20260816.json; pdf-raw/ade/ade_species_slice_expand_2026-08-16.json","trust":{"authority_tier":"ungraded","fidelity":"verbatim","license":"open dataset (FDA openFDA, public domain)","display_grade":"pending"},"tokens_estimated":488,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}